2026 Q2 - tulosraportti
36 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 900 | - | - | ||
| 1 284 | - | - | ||
| 5 000 | - | - | ||
| 1 828 | - | - | ||
| 704 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·34 min sittenIt will be an exciting autumn/winter: • The academic annual meeting (The major scientific news): The upcoming ESGCT annual meeting (European Society of Gene and Cell Therapy) takes place in Hamburg, Germany at Congress Center Hamburg (CCH). This event takes place at the end of the month, from October 27 to 30, 2026. It is thus at the latter in Germany that Circio officially unveils their major scientific details during an oral presentation. With help from ChatGbt, who had dug it up.
·5 t sittenCircio Holding ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at steadily higher prices to enter the stock and indicates a good development for the company. The stock is approaching resistance at approximately 14.30 kroner, which may trigger a downward reaction. A breakout above 14.30 kroner would, however, be a buy signal. The RSI curve shows a falling trend, which is an early signal of a possible downward turn in the price as well. https://www.investtech.com/no/market.php?CompanyID=100758&tck=CRNA
- ·10 t sitten · MuokattuCircio has installed a new and advanced flow cytometry machine (BD FACSDiscover A7). According to LinkedIn, this is the first machine of its type in the region, and also the first order placed in Europe and the USA. Flow cytometry is an important tool for the characterization of T cells and CAR expression. Fits well with their capacity building on the in vivo CAR-T side. ------------------------ Direct copy from LinkedIn Celebrating Circio as first adopters of the latest flow cytometry technology Today, we celebrated the installation of Circio's new BD FACSDiscover' A7 Cell Analyzer. Not only is this the first FACSDiscover A7 installed in the region, but it also represents the first FACSDiscover A7 order placed in Europe and the US, making this a truly special milestone. A special thank you to Ola Melin, COO of Circio, for sharing the team's vision for how the A7 will help advance their research and support future discoveries. We're proud to support Circio on this journey and look forward to seeing the discoveries ahead. Congratulations to the entire Circio team! #FACSDiscoverA7 #FlowCytometry #SpectralFlowCytometry #CellAnalysis #WatersBiosciences #BDBiosciences #Circio https://www.linkedin.com/posts/mikael-mikko-8a057759_facsdiscovera7-flowcytometry-spectralflowcytometry-ugcPost-7513233922101501952-BybM/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7513233977005191169&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUHave looked a bit closer at this. Thomas has previously mentioned that they were waiting for a new machine this month to move forward with the characterization of T-cells in spleen. In the Q3 presentation, it already stated that «spleen cell type characterization» was underway. Now they have put in place the tool needed to do that job properly. Regarding ESGCT in three weeks: The abstracts were submitted long ago, so data from this machine will not make it in there. But they can update slides during the presentation itself if they manage to generate something. That is common practice. ( Expect spleen is included but cannot guarantee it. ) Positive that they are building capacity internally on the CAR-T side.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
36 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·34 min sittenIt will be an exciting autumn/winter: • The academic annual meeting (The major scientific news): The upcoming ESGCT annual meeting (European Society of Gene and Cell Therapy) takes place in Hamburg, Germany at Congress Center Hamburg (CCH). This event takes place at the end of the month, from October 27 to 30, 2026. It is thus at the latter in Germany that Circio officially unveils their major scientific details during an oral presentation. With help from ChatGbt, who had dug it up.
- ·5 t sittenCircio Holding ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at steadily higher prices to enter the stock and indicates a good development for the company. The stock is approaching resistance at approximately 14.30 kroner, which may trigger a downward reaction. A breakout above 14.30 kroner would, however, be a buy signal. The RSI curve shows a falling trend, which is an early signal of a possible downward turn in the price as well. https://www.investtech.com/no/market.php?CompanyID=100758&tck=CRNA
- ·10 t sitten · MuokattuCircio has installed a new and advanced flow cytometry machine (BD FACSDiscover A7). According to LinkedIn, this is the first machine of its type in the region, and also the first order placed in Europe and the USA. Flow cytometry is an important tool for the characterization of T cells and CAR expression. Fits well with their capacity building on the in vivo CAR-T side. ------------------------ Direct copy from LinkedIn Celebrating Circio as first adopters of the latest flow cytometry technology Today, we celebrated the installation of Circio's new BD FACSDiscover' A7 Cell Analyzer. Not only is this the first FACSDiscover A7 installed in the region, but it also represents the first FACSDiscover A7 order placed in Europe and the US, making this a truly special milestone. A special thank you to Ola Melin, COO of Circio, for sharing the team's vision for how the A7 will help advance their research and support future discoveries. We're proud to support Circio on this journey and look forward to seeing the discoveries ahead. Congratulations to the entire Circio team! #FACSDiscoverA7 #FlowCytometry #SpectralFlowCytometry #CellAnalysis #WatersBiosciences #BDBiosciences #Circio https://www.linkedin.com/posts/mikael-mikko-8a057759_facsdiscovera7-flowcytometry-spectralflowcytometry-ugcPost-7513233922101501952-BybM/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7513233977005191169&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUHave looked a bit closer at this. Thomas has previously mentioned that they were waiting for a new machine this month to move forward with the characterization of T-cells in spleen. In the Q3 presentation, it already stated that «spleen cell type characterization» was underway. Now they have put in place the tool needed to do that job properly. Regarding ESGCT in three weeks: The abstracts were submitted long ago, so data from this machine will not make it in there. But they can update slides during the presentation itself if they manage to generate something. That is common practice. ( Expect spleen is included but cannot guarantee it. ) Positive that they are building capacity internally on the CAR-T side.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 900 | - | - | ||
| 1 284 | - | - | ||
| 5 000 | - | - | ||
| 1 828 | - | - | ||
| 704 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
36 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·34 min sittenIt will be an exciting autumn/winter: • The academic annual meeting (The major scientific news): The upcoming ESGCT annual meeting (European Society of Gene and Cell Therapy) takes place in Hamburg, Germany at Congress Center Hamburg (CCH). This event takes place at the end of the month, from October 27 to 30, 2026. It is thus at the latter in Germany that Circio officially unveils their major scientific details during an oral presentation. With help from ChatGbt, who had dug it up.
- ·5 t sittenCircio Holding ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at steadily higher prices to enter the stock and indicates a good development for the company. The stock is approaching resistance at approximately 14.30 kroner, which may trigger a downward reaction. A breakout above 14.30 kroner would, however, be a buy signal. The RSI curve shows a falling trend, which is an early signal of a possible downward turn in the price as well. https://www.investtech.com/no/market.php?CompanyID=100758&tck=CRNA
- ·10 t sitten · MuokattuCircio has installed a new and advanced flow cytometry machine (BD FACSDiscover A7). According to LinkedIn, this is the first machine of its type in the region, and also the first order placed in Europe and the USA. Flow cytometry is an important tool for the characterization of T cells and CAR expression. Fits well with their capacity building on the in vivo CAR-T side. ------------------------ Direct copy from LinkedIn Celebrating Circio as first adopters of the latest flow cytometry technology Today, we celebrated the installation of Circio's new BD FACSDiscover' A7 Cell Analyzer. Not only is this the first FACSDiscover A7 installed in the region, but it also represents the first FACSDiscover A7 order placed in Europe and the US, making this a truly special milestone. A special thank you to Ola Melin, COO of Circio, for sharing the team's vision for how the A7 will help advance their research and support future discoveries. We're proud to support Circio on this journey and look forward to seeing the discoveries ahead. Congratulations to the entire Circio team! #FACSDiscoverA7 #FlowCytometry #SpectralFlowCytometry #CellAnalysis #WatersBiosciences #BDBiosciences #Circio https://www.linkedin.com/posts/mikael-mikko-8a057759_facsdiscovera7-flowcytometry-spectralflowcytometry-ugcPost-7513233922101501952-BybM/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7513233977005191169&highlightedUpdateType=SOCIAL_SHARE&origin=SOCIAL_SHARE&utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUHave looked a bit closer at this. Thomas has previously mentioned that they were waiting for a new machine this month to move forward with the characterization of T-cells in spleen. In the Q3 presentation, it already stated that «spleen cell type characterization» was underway. Now they have put in place the tool needed to do that job properly. Regarding ESGCT in three weeks: The abstracts were submitted long ago, so data from this machine will not make it in there. But they can update slides during the presentation itself if they manage to generate something. That is common practice. ( Expect spleen is included but cannot guarantee it. ) Positive that they are building capacity internally on the CAR-T side.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 900 | - | - | ||
| 1 284 | - | - | ||
| 5 000 | - | - | ||
| 1 828 | - | - | ||
| 704 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt